Rosuvastatin/ezetimibe combines two lipid-lowering agents: rosuvastatin, an HMG-CoA
reductase inhibitor (ie statin) with particularly strong inhibitory effects on hepatic cholesterol …

Introduction: Reducing low-density lipoprotein cholesterol (LDL-C) with lipid-lowering
therapies has been associated with a decrease in the frequency of cardiovascular events …

This study aimed to compare and evaluate the efficacy of the blood pressure (BP) control
and cholesterol‐lowering effects and safety of combination therapy with telmisartan …

Background To investigate the efficacy and safety of moderate-intensity
rosuvastatin/ezetimibe combination compared to highintensity rosuvastatin in high …

Purpose There are few studies in the literature on the dosage of statin that equivalently
reduces low-density lipoprotein cholesterol (LDL-C) compared to an ezetimibe combination …

Vascular diseases are the leading cause of death in Spain. Hypercholesterolemia is not only
a cardiovascular risk factor, but also underlies the etiopathogenesis of atherosclerosis …

This study aimed to investigate the impact of the latest guidelines on the real-world clinical
practice of initial lipid-lowering therapy, especially on the use of ezetimibe and proprotein …

摘要目的: 探讨超声引导下腰骶丛神经阻滞联合全身麻醉对老年髋关节置换术患者认知功能,
氧化应激和血流动力学的影响. 方法: 选取2018 年1 月~ 2020 年1 月期间我院收治的80 …

摘要目的: 探讨降脂通脉胶囊联合瑞舒伐他汀治疗冠心病合并颈动脉粥样硬化斑块的临床疗效.
方法: 选取2018 年2 月~ 2019 年10 月期间我院收治的冠心病合并颈动脉粥样硬化斑块患者80 …

Objective: To assess the clinical effect and safety of double anti-platelet therapy combined
with different doses of statins for acute cerebral infarction complicated with …